Clinical Efficacy of Niuhuang Chengqitang in Treatment of Acute Gastrointestinal Injury in Patients with Severe Traumatic Brain Injury and Its Effect on MTL, DAO, and NSE
|更新时间:2022-11-17
|
Clinical Efficacy of Niuhuang Chengqitang in Treatment of Acute Gastrointestinal Injury in Patients with Severe Traumatic Brain Injury and Its Effect on MTL, DAO, and NSE
Chinese Journal of Experimental Traditional Medical FormulaeVol. 28, Issue 24, Pages: 131-137(2022)
HE Jinbo,MAO Zhengrong,AI Shen.Clinical Efficacy of Niuhuang Chengqitang in Treatment of Acute Gastrointestinal Injury in Patients with Severe Traumatic Brain Injury and Its Effect on MTL, DAO, and NSE[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(24):131-137.
HE Jinbo,MAO Zhengrong,AI Shen.Clinical Efficacy of Niuhuang Chengqitang in Treatment of Acute Gastrointestinal Injury in Patients with Severe Traumatic Brain Injury and Its Effect on MTL, DAO, and NSE[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(24):131-137. DOI: 10.13422/j.cnki.syfjx.20222492.
Clinical Efficacy of Niuhuang Chengqitang in Treatment of Acute Gastrointestinal Injury in Patients with Severe Traumatic Brain Injury and Its Effect on MTL, DAO, and NSE
To evaluate the clinical efficacy of Niuhuang Chengqitang in the treatment of acute gastrointestinal injury (AGI) in patients with severe traumatic brain injury (sTBI) and observe the effect on serum motilin (MTL), diamine oxidase (DAO), and neuron-specific enolase (NSE).
Method
2
By the prospective randomized controlled trial (RCT) method, 86 sTBI inpatients with AGI were randomly divided into an observation group(43 cases)and a control group (43 cases). All patients were given conventional western medicine treatment, including actively targeting the primary diseases and combined diseases, supply of enteral nutrition as soon as possible, and gastrointestinal agents, while those in the observation group received additional Niuhuang Chengqitang by nasal administration. The treatment course of both groups was 7 days. The clinical efficacy of the two groups was compared before treatment and 7 days after treatment. Gastrointestinal failure (GIF) score and intra-abdominal pressure (IAP) of the two groups were recorded, and serum MTL, DAO and NSE levels were detected before treatment, 3 days and 7 days after treatment. The Glasgow Coma Scale (GCS) score, duration of mechanical ventilation, length of ICU stay, and 28-day mortality were recorded.
Result
2
During the treatment and observation, 4 cases fell off and 82 cases were finally enrolled, including 41 in the observation group and 41 in the control group. After treatment, the total effective rate in the observation group was 80.49%(33/41), higher than 56.10%(23/41) in the control group (
χ
2
=9.137,
P
<
0.05). GIF and IAP scores in the observation group were significantly improved after 3 and 7 days of treatment (
P
<
0.01), and the observation group was superior to the control group after 7 days of treatment (
P
<
0.05). The serum levels of MTL, DAO, and NSE in the two groups were improved after 3 and 7 days of treatment (
P
<
0.05,
P
<
0.01). The levels of MTL and NSE in the observation group were better than those in the control group after 3 days of treatment (
P
<
0.05,
P
<
0.01), and the levels of MTL, DAO, and NSE in the observation group were superior to those in the control group after 7 days of treatment (
P
<
0.05,
P
<
0.01). The 28-day GCS score in the observation group was higher than that in the control group (
P
<
0.01), and the duration of mechanical ventilation and ICU stay in the observation group were significantly shorter than those in the control group (
P
<
0.05). There was no significant difference in 28-day mortality between the two groups. No adverse reactions related to Niuhuang Chengqitang occurred in the observation group.
Conclusion
2
Niuhuang Chengqitang can effectively improve the gastrointestinal function, regulate MTL, DAO, and NSE levels, shorten the ICU stay, and promote the recovery of sTBI patients with AGI.
关键词
Keywords
references
GEURTS M , MACLEOD M R , VAN THIEL G J , et al . End-of-life decisions in patients with severe acute brain injury [J]. Lancet Neurol , 2014 , 13 ( 5 ): 515 - 524 .
REINTAM BLASER A , MALBRAIN M L , STARKOPF J , et al . Gastrointestinal function in intensive care patients:Terminology,definitions and management.Recommendations of the ESICM Working Group on abdominal problems [J]. Intensive Care Med , 2012 , 38 ( 3 ): 384 - 394 .
LI H , SUN J , DU J , et al . Clostridium butyricum exerts a neuroprotective effect in a mouse model of traumatic brain injury via the gut-brain axis [J]. Neurogastroenterol Motil , 2018 , 30 ( 5 ): e13260 .
MENEGHINI F , STELLIN L . Multiple system organ failure [J]. Ann Surg , 1993 , 218 ( 5 ): 698 - 699 .
REINTAM A , PARM P , KITUS R , et al . Gastrointestinal failure score in critically ill patients:A prospective observational study [J]. Crit Care , 2008 , 12 ( 4 ): R90 .
KRON I L , HARMAN P K , NOLAN S P . The measurement of intra-abdominal pressure as a criterion for abdominal re-exploration [J]. Ann Surg , 1984 , 199 ( 1 ): 28 - 30 .
MENG Y , ZHANG Y , LIU M , et al . Evaluating intestinal permeability by measuring plasma endotoxin and diamine oxidase in children with acute lymphoblastic leukemia treated with high-dose methotrexate [J]. Anticancer Agents Med Chem , 2016 , 16 ( 3 ): 387 - 392 .
OLIVECRONA Z , BOBINSKI L , KOSKINEN L O . Association of ICP,CPP,CT findings and S-100B and NSE in severe traumatic head injury.Prognostic value of the biomarkers [J]. Brain Inj , 2015 , 29 ( 4 ): 446 - 454 .
RODRÍGUEZ-RODRÍGUEZ A , EGEA-GUERRERO J J , GORDILLO-ESCOBAR E , et al . S100B and Neuron-specific enolase as mortality predictors in patients with severe traumatic brain injury [J]. Neurol Res , 2016 , 38 ( 2 ): 130 - 137 .